Carter Gould
Stock Analyst at Barclays
(2.32)
# 1,458
Out of 4,667 analysts
199
Total ratings
41.18%
Success rate
-0.89%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Equal-Weight | $84 → $95 | $88.63 | +7.19% | 14 | Nov 7, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,080 → $1,065 | $743.35 | +43.27% | 19 | Nov 1, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $18 → $20 | $17.86 | +11.98% | 6 | Nov 1, 2024 | |
| LLY Eli Lilly | Maintains: Overweight | $1,025 → $975 | $753.41 | +29.41% | 11 | Oct 31, 2024 | |
| BIIB Biogen | Maintains: Equal-Weight | $190 → $180 | $156.00 | +15.38% | 24 | Oct 31, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $42 → $43 | $57.88 | -25.71% | 14 | Oct 7, 2024 | |
| MRK Merck & Co. | Maintains: Overweight | $142 → $140 | $97.44 | +43.68% | 10 | Oct 7, 2024 | |
| AMGN Amgen | Maintains: Equal-Weight | $300 → $315 | $287.87 | +9.42% | 16 | Oct 7, 2024 | |
| ABBV AbbVie | Maintains: Overweight | $200 → $212 | $167.76 | +26.37% | 14 | Oct 7, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $180 → $160 | $123.29 | +29.78% | 11 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $100 | $91.17 | +9.69% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $3 | $0.79 | +277.45% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $32 | $24.94 | +28.31% | 14 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $0.90 | +233.70% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $3.99 | +125.56% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $49.86 | +90.53% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $14.55 | +37.46% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $87.22 | -16.30% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $1.5 → $1 | $0.94 | +6.47% | 4 | Jan 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $3.64 | +230.12% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $0.70 | +115.36% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $68 → $15 | $0.39 | +3,765.98% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $9.43 | -76.14% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $219.78 | +72.90% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $71.05 | +15.41% | 5 | Jan 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $183 → $188 | $451.23 | -58.34% | 1 | Jul 26, 2018 |
Gilead Sciences
Nov 7, 2024
Maintains: Equal-Weight
Price Target: $84 → $95
Current: $88.63
Upside: +7.19%
Regeneron Pharmaceuticals
Nov 1, 2024
Maintains: Overweight
Price Target: $1,080 → $1,065
Current: $743.35
Upside: +43.27%
Travere Therapeutics
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $17.86
Upside: +11.98%
Eli Lilly
Oct 31, 2024
Maintains: Overweight
Price Target: $1,025 → $975
Current: $753.41
Upside: +29.41%
Biogen
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $156.00
Upside: +15.38%
Bristol-Myers Squibb Company
Oct 7, 2024
Maintains: Underweight
Price Target: $42 → $43
Current: $57.88
Upside: -25.71%
Merck & Co.
Oct 7, 2024
Maintains: Overweight
Price Target: $142 → $140
Current: $97.44
Upside: +43.68%
Amgen
Oct 7, 2024
Maintains: Equal-Weight
Price Target: $300 → $315
Current: $287.87
Upside: +9.42%
AbbVie
Oct 7, 2024
Maintains: Overweight
Price Target: $200 → $212
Current: $167.76
Upside: +26.37%
Neurocrine Biosciences
Sep 9, 2024
Maintains: Overweight
Price Target: $180 → $160
Current: $123.29
Upside: +29.78%
Aug 29, 2024
Initiates: Overweight
Price Target: $100
Current: $91.17
Upside: +9.69%
Aug 14, 2024
Maintains: Overweight
Price Target: $10 → $3
Current: $0.79
Upside: +277.45%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $30 → $32
Current: $24.94
Upside: +28.31%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $0.90
Upside: +233.70%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $3.99
Upside: +125.56%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $49.86
Upside: +90.53%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $14.55
Upside: +37.46%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $87.22
Upside: -16.30%
Jan 17, 2024
Maintains: Underweight
Price Target: $1.5 → $1
Current: $0.94
Upside: +6.47%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $3.64
Upside: +230.12%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $0.70
Upside: +115.36%
Nov 11, 2022
Maintains: Overweight
Price Target: $68 → $15
Current: $0.39
Upside: +3,765.98%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $9.43
Upside: -76.14%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $219.78
Upside: +72.90%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $71.05
Upside: +15.41%
Jul 26, 2018
Maintains: Neutral
Price Target: $183 → $188
Current: $451.23
Upside: -58.34%